ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management
Authors:
Open Access
- 10 November 2015
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 16 (3) , 886-896
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- ABO-incompatible kidney transplantationTransplantation Reviews, 2013
- Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous ImmunoglobulinClinical Journal of the American Society of Nephrology, 2011
- Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experienceNephrology Dialysis Transplantation, 2011
- The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experienceClinical Transplantation, 2010
- Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant PatientsAmerican Journal of Transplantation, 2009
- Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipientsTransplant International, 2009
- Evaluation of Two Different Preconditioning Regimens for ABO-Incompatible Living Kidney Donor Transplantation2008
- Evaluation of Immunosuppressive Regimens in ABO-Incompatible Living Kidney Transplantation—Single Center AnalysisAmerican Journal of Transplantation, 2007
- Excellent Long-term Outcome of ABO-Incompatible Living Donor Kidney Transplantation in JapanAmerican Journal of Transplantation, 2004
- Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity1Transplantation, 2002